This Article Full Text Full Text (PDF) Correction (v115,pe31) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Granger, C. B. Search for Related Content PubMed PubMed Citation Articles by Granger, C. B. Related Collections Other Treatment

(Circulation. 2006;114:2432-2433.)
© 2006 American Heart Association, Inc.

Editorial

Prediction and Prevention of Chemotherapy-Induced Cardiomyopathy

Can It Be Done?

Christopher B. Granger, MD

From the Duke Clinical Research Institute, Durham, NC.

Correspondence to Christopher B. Granger, MD, Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705. E-mail grang001@dcri.duke.edu

Key Words: Editorials • cardiomyopathy • prevention • trials • angiotensin

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Although anthracyclines are highly effective at treating certain cancers, their use is limited by the potential for cardiotoxicity. Studies report a wide range of the incidence of cardiotoxicity, related to differences in definitions, chemotherapy regimens, and patient populations. The occurrence of clinical heart failure seems to be in the range of 1% to 5%, and asymptomatic decrease in left ventricular function is in the range of 5% to 20%.^1,2 Toxicity can occur early (within 1 year) or late (particularly among children, where late cardiac abnormalities are detectable in two thirds of surviving patients).³ The occurrence of cardiomyopathy is related to cumulative dose of anthracycline (especially doxorubicin doses >550 mg/m²), dosing schedule, age, gender, mediastinal irradiation, and combination with other agents, including trastuzumab.⁴ Other chemotherapy, including imatinib mesylate,⁵ can also cause cardiotoxicity, suggesting a broader potential for adverse cardiac effects from novel chemotherapy and, especially, from inhibitors of nonreceptor tyrosine kinases. Anthracycline-induced cardiomyopathy seems to have a similar impact on survival as other forms of heart failure.⁶ Thus, identification of individuals at risk, prevention, early diagnosis, and effective treatment are all important goals. Most of these needs have been addressed by uncontrolled or small studies, and guidelines have relatively sparse information on which to base recommendations for care, other than careful monitoring of left ventricular function and interrupting or discontinuing anthracyclines once significant decrease in ejection fraction is detected, which is often too late.⁷

Article p 2474

Cardinale et al² have addressed 2 of the challenges: How does one identify . . . [Full Text of this Article]

This article has been cited by other articles:

				A. Riad, S. Bien, D. Westermann, P. M. Becher, K. Loya, U. Landmesser, H. K. Kroemer, H. P. Schultheiss, and C. Tschope Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice Cancer Res., January 15, 2009; 69(2): 695 - 699. [Abstract] [Full Text] [PDF]

				A. Riad, S. Bien, M. Gratz, F. Escher, M. M. Heimesaat, S. Bereswill, T. Krieg, S. B. Felix, H. P. Schultheiss, H. K. Kroemer, et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice Eur J Heart Fail, March 1, 2008; 10(3): 233 - 243. [Abstract] [Full Text] [PDF]